T2 Biosystems, Inc. (TTOO)
| Market Cap | 28.05K -75.0% |
| Revenue (ttm) | 7.68M -30.2% |
| Net Income | -42.95M |
| EPS | -4.08 |
| Shares Out | 28.05M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 35 |
| Open | 0.0010 |
| Previous Close | 0.0010 |
| Day's Range | 0.0010 - 0.0115 |
| 52-Week Range | 0.0001 - 0.0800 |
| Beta | 7.83 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 31, 2026 |
About T2 Biosystems
T2 Biosystems, Inc. engages in the development and commercialization of medical diagnostic products for critical unmet needs in the healthcare. Its products include T2Dx instrument, T2Candida panel, and T2Bacteria panel. The company was incorporated in 2006 and is based in Lexington, Massachusetts. [Read more]
Financial Performance
In 2023, T2 Biosystems's revenue was $7.19 million, a decrease of -67.75% compared to the previous year's $22.31 million. Losses were -$50.08 million, -19.66% less than in 2022.
Financial StatementsNews
T2 Biosystems Earnings release: Q4 2024
T2 Biosystems released its Q4 2024 earnings on January 7, 2025, summarizing the period's financial results.
T2 Biosystems reports preliminary Q4 revenue $2.3M
“We made considerable progress across the business during 2024, increasing our global installed base of T2Dx Instruments, and generating record sales for our sepsis test panels, including record U.S. ...
T2 Biosystems announces sale of four T2Dx Intruments to European distributor
T2 Biosystems (TTOO) announced the sale of four T2Dx Instruments to its European distributor that represents multiple EU counties, demonstrating commercial expansion and increased international market...
T2 Biosystems achieves milestone with 250,000th novel sepsis test shipped
T2 Biosystems (TTOO) announced that it has surpassed the shipment of 250,000 sepsis tests, marking a significant milestone that underscores the growing customer adoption of the Company’s direct-from-w...
T2 Biosystems extends multi-year supplier agreement with Vizient
T2 Biosystems (TTOO) announced that its multi-year capital equipment supplier agreement with Vizient has been extended through March 31, 2026. The products covered under the contract with Vizient incl...
T2 Biosystems announces plans to license technology to expand its leadership
T2 Biosystems (TTOO) announced plans to license its proprietary technology to expand its leadership in direct-from-whole-blood detection of sepsis-causing pathogens. T2 Biosystems’ proprietary technol...
T2 Biosystems Earnings Call Transcript: Q3 2024
Q3 2024 revenue grew 34% year-over-year, driven by strong sepsis test and international instrument sales. Exclusive U.S. distribution with Cardinal Health and a co-marketing deal with Precision Inc. are expected to accelerate growth, with new product launches and FDA submissions planned for 2025.
T2 Biosystems Earnings release: Q3 2024
T2 Biosystems released its Q3 2024 earnings on November 14, 2024, summarizing the period's financial results.
T2 Biosystems Quarterly report: Q3 2024
T2 Biosystems has published its Q3 2024 quarterly earnings report on November 14, 2024.
T2 Biosystems Transcript: Status Update
Exclusive U.S. distribution with Cardinal Health and a new AI collaboration with Precision Inc. are expected to drive growth and expand market reach. Q3 revenue rose 35% year-over-year, with strong sepsis panel sales and new FDA clearance for pediatric use.
T2 Biosystems, Prxcision announce co-marketing collaboration
T2 Biosystems and Prxcision have announced a co-marketing collaboration intended to deliver a revolutionary solution for patients suspected of bloodstream infections and sepsis, and combat the escalat...
T2 Biosystems sees Q3 revenue $2M, up 35% compared to 3Q23
T2 Biosystems announced preliminary unaudited financial and operational results for the third quarter 2024. Recent Financial and Operational Highlights: Achieved third quarter total revenue of $2.0 mi...
T2 Biosystems sees Q4 sepsis product revenue $2.5M-$3.5M
The Company now expects fourth quarter 2024 total sepsis product revenue of $2.5 million to $3.5 million, representing growth of 49% to 109% compared to the fourth quarter of 2023.
T2 Biosystems enters exclusive U.S. agreement with Cardinal Health
T2 Biosystems (TTOO) has entered into a multi-year exclusive U.S. agreement with Cardinal Health (CAH),. Under the agreement, Cardinal Health will have exclusive rights to sell T2 Biosystems’ FDA-clea...
T2 Biosystems announces publication of article in The Lancet
T2 Biosystems highlighted a recently published article in The Lancet, a world-leading medical journal. The article titled “Changing the Culture of Blood Culture” was authored by Sally Davies, Richard ...
T2 Biosystems achieves successful defense against key patent
T2 Biosystems announced that it has successfully defended against an opposition filed against a key patent for its direct-from-whole blood detection method in the European Union. The opposition was fi...
T2 Biosystems receives FDA clearance to market the T2Candida Panel
T2 Biosystems announced that it has received clearance from the U.S. Food and Drug Administration, FDA, to market its FDA-cleared T2Candida Panel for pediatric patients. The Company expects to immedia...
T2 Biosystems provides update on product development pipeline progress
T2 Biosystems provided an update on its new product development pipeline progress. The Company’s product pipeline is focused on direct-from-blood diagnostic tests for antimicrobial resistance, pediatr...
T2 Biosystems Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024
Presented unique FDA-cleared diagnostics for rapid sepsis detection, with strong clinical evidence of faster treatment and reduced hospital stays. Operational improvements and global expansion support record revenue growth, with new products and partnerships planned for 2024.
T2 Biosystems Transcript: Sidoti Micro-Cap Virtual Conference
A cutting-edge diagnostic platform enables rapid, direct-from-blood sepsis detection, bypassing slow and supply-constrained blood cultures. Recent clinical studies show significant reductions in time to targeted therapy and hospital stays. Strategic partnerships, new product launches, and operational improvements are expected to drive growth and financial stability.
T2 Biosystems Transcript: Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 2024
Sepsis remains a critical and costly challenge for hospitals, with rapid, culture-independent diagnostics offering significant clinical and financial benefits. Key growth drivers include global expansion, new product launches (T2Lyme, T2Resistance), and a major US partnership, with strong second-half 2024 performance expected.
T2 Biosystems price target raised to $5 from $3 at Canaccord
Canaccord raised the firm’s price target on T2 Biosystems to $5 from $3 and keeps a Hold rating on the shares. The analyst cites improved margin assumptions in its 10-year…
T2 Biosystems Earnings Call Transcript: Q2 2024
Q2 2024 saw record sepsis test revenue and strong international expansion, with 27% year-over-year growth and significant cost reductions. The company is pursuing a major U.S. partnership, launching new products, and expects 49–64% revenue growth for 2024.
T2 Biosystems Quarterly report: Q2 2024
T2 Biosystems has published its Q2 2024 quarterly earnings report on July 29, 2024.
T2 Biosystems Earnings release: Q2 2024
T2 Biosystems released its Q2 2024 earnings on July 29, 2024, summarizing the period's financial results.